Literature DB >> 30219327

A Randomized Trial to Assess Regional Left Ventricular Function After Stent Implantation in Chronic Total Occlusion: The REVASC Trial.

Kambis Mashayekhi1, Thomas G Nührenberg2, Aurel Toma2, Michael Gick2, Miroslaw Ferenc2, Willibald Hochholzer2, Thomas Comberg2, Jürgen Rothe2, Christian M Valina2, Nikolaus Löffelhardt2, Mohammed Ayoub2, Min Zhao2, Johannes Bremicker2, Nikolaus Jander2, Jan Minners2, Philipp Ruile2, Michael Behnes3, Ibrahim Akin3, Tim Schäufele4, Franz-Josef Neumann2, Heinz Joachim Büttner2.   

Abstract

OBJECTIVES: The aim of this study was to investigate whether percutaneous coronary intervention (PCI) of chronic total occlusions (CTOs) improves left ventricular function.
BACKGROUND: The benefit of PCI in CTOs is still controversial.
METHODS: Patients with CTOs who were candidates for PCI were eligible for the study and were randomized to PCI or no PCI of CTO. Relevant coexisting non-CTO lesions were treated as indicated. Patients underwent cardiac magnetic resonance imaging at baseline and at 6 months. The primary endpoint was the change in segmental wall thickening (SWT) in the CTO territory. Secondary endpoints were improvement of regional wall motion and changes in left ventricular volumes and ejection fraction. Furthermore, major adverse coronary events after 12 months were assessed.
RESULTS: The CTO PCI group comprised 101 patients and the no CTO PCI group 104 patients. The change in SWT did not differ between the CTO PCI (4.1% [interquartile range: 14.6 to 19.3]) and no CTO PCI (6.0% [interquartile range: 8.6 to 6.0]) groups (p = 0.57). Similar results were obtained for other indexes of regional and global left ventricular function. Subgroup analysis revealed that only in patients without major non-CTO lesions (basal SYNTAX [Synergy Between Percutaneous Coronary Intervention With Taxus and Cardiac Surgery] score ≤13) CTO PCI was associated with larger improvement in SWT than no CTO PCI (p for interaction = 0.002). Driven by repeat intervention, major adverse coronary event rates at 12 months were significantly lower in the CTO PCI group (16.3% vs. 5.9%; p = 0.02).
CONCLUSIONS: No benefit was seen for CTO PCI in terms of the primary endpoint, SWT, or other indexes of left ventricular function. CTO PCI resulted in clinical benefit over no CTO PCI, as evidenced by reduced major adverse coronary event rates at 12 months.
Copyright © 2018 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cardiovascular magnetic resonance imaging; chronic total occlusion; percutaneous coronary intervention; randomized trial; segmental wall thickening

Mesh:

Year:  2018        PMID: 30219327     DOI: 10.1016/j.jcin.2018.05.041

Source DB:  PubMed          Journal:  JACC Cardiovasc Interv        ISSN: 1936-8798            Impact factor:   11.195


  16 in total

Review 1.  A contemporary review of clinical significances of percutaneous coronary intervention for chronic total occlusions, with some Japanese insights.

Authors:  Yoshihiro Morino
Journal:  Cardiovasc Interv Ther       Date:  2021-03-03

2.  The year in cardiology 2018: coronary interventions.

Authors:  Dariusz Dudek; Artur Dziewierz; Gregg Stone; William Wijns
Journal:  Eur Heart J       Date:  2019-01-07       Impact factor: 29.983

Review 3.  The indications and utility of adjunctive imaging modalities for chronic total occlusion (CTO) intervention.

Authors:  Usaid K Allahwala; Emmanouil S Brilakis; Hosen Kiat; Sally Ayesa; Daniel Nour; Michael Ward; Sidney Lo; James C Weaver; Ravinay Bhindi
Journal:  J Nucl Cardiol       Date:  2020-10-06       Impact factor: 5.952

Review 4.  CTO in Contemporary PCI.

Authors:  Mohamed Farag; Mohaned Egred
Journal:  Curr Cardiol Rev       Date:  2022

5.  Improvement of left ventricular function assessment by global longitudinal strain after successful percutaneous coronary intervention for chronic total occlusion.

Authors:  Misato Chimura; Shinichiro Yamada; Yoshinori Yasaka; Hiroya Kawai
Journal:  PLoS One       Date:  2019-06-12       Impact factor: 3.240

6.  Percutaneous Coronary Intervention Versus Medical Therapy for Chronic Total Occlusion of Coronary Arteries: A Systematic Review and Meta-Analysis.

Authors:  Ka Hou Christien Li; Ka Hei Gabriel Wong; Mengqi Gong; Tong Liu; Guangping Li; Yunlong Xia; Jeffery Ho; Luis Nombela-Franco; Abhishek C Sawant; Simon Eccleshall; Gary Tse; Vassilios S Vassiliou
Journal:  Curr Atheroscler Rep       Date:  2019-08-09       Impact factor: 5.113

Review 7.  Chronic total occlusion percutaneous coronary intervention in everyday clinical practice - an expert opinion of the Association of Cardiovascular Interventions of the Polish Cardiac Society.

Authors:  Leszek Bryniarski; Maksymilian P Opolski; Jarosław Wójcik; Maciej Lesiak; Tomasz Pawłowski; Jakub Drozd; Wojciech Wojakowski; Sławomir Surowiec; Maciej Dąbrowski; Adam Witkowski; Dariusz Dudek; Marek Grygier; Stanisław Bartuś
Journal:  Postepy Kardiol Interwencyjnej       Date:  2021-03-27       Impact factor: 1.426

8.  Circulating Chromogranin B Is Associated With Left Ventricular Functional Recovery After Successful Recanalization of Chronic Total Occlusion.

Authors:  Ying Shen; Muladili Aihemaiti; Xin Yi Shu; Chen Die Yang; Jia Wei Chen; Yang Dai; Feng Hua Ding; Zhen Kun Yang; Jian Hu; Rui Yan Zhang; Lin Lu; Xiao Qun Wang; Wei Feng Shen
Journal:  Front Cardiovasc Med       Date:  2021-12-24

9.  A comparison of long-term clinical outcomes between percutaneous coronary intervention (PCI) and medical therapy in patients with chronic total occlusion in noninfarct-related artery after PCI of acute myocardial infarction.

Authors:  Qing Qin; Lu Chen; Lei Ge; Juying Qian; Jianying Ma; Junbo Ge
Journal:  Clin Cardiol       Date:  2022-01-06       Impact factor: 2.882

10.  Viability and functional recovery after chronic total occlusion percutaneous coronary intervention.

Authors:  Stefan P Schumacher; Henk Everaars; Wijnand J Stuijfzand; Pepijn A van Diemen; Roel S Driessen; Michiel J Bom; Ruben W de Winter; Yvemarie B O Somsen; Jennifer W Huynh; Ramon B van Loon; Peter M van de Ven; Albert C van Rossum; Maksymilian P Opolski; Alexander Nap; Paul Knaapen
Journal:  Catheter Cardiovasc Interv       Date:  2021-07-30       Impact factor: 2.585

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.